Innovent Announces First Patient Dosed in a Phase 2 Clinical study of IBI112 (IL-23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Active Ulcerative Colitis ...Middle East

SAN FRANCISCO and SUZHOU, China , July 3, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, autoimmune, metabolic,...

Hence then, the article about innovent announces first patient dosed in a phase 2 clinical study of ibi112 il 23p19 monoclonal antibody in patients with moderate to severe active ulcerative colitis was published today ( Monday 04/07/2022 - 03:56 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent Announces First Patient Dosed in a Phase 2 Clinical study of IBI112 (IL-23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Active Ulcerative Colitis )

Also on site :

• ‘World of Warcraft’ Just Upgraded Its Best City for the First Time in 20 Years, and Now It’s Perfect
• Denver’s historic Brown Palace Hotel listed for sale
• White House Mocks Kesha Over Singer’s Outrage About “Disgusting” Use Of Song In Military Posting; She Responds: “Stop Using My Music, Perverts”